Syndax Leverages Novel IP for Cash, Phase II HDAC

Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.

Prying clinical-stage assets—even ones given up for dead—out of the steely grasps of pharmaceutical companies remains a tedious and difficult proposition; it’s hardly ever the smoothest of negotiations. Identifying that special project—the one that inspires the perfect blend of biotech excitement and pharmaco-nonchalance—is only the first hurdle. Many biotech attempts to out-license pharmaceutical candidates turn out to be fruitless: the pharma changes its mind, the biotech can’t come up with a reasonable strategy for the compound, or a fair deal can’t be worked out.

Pharma’s reluctance is well documented, which makes those successful deals all the more noteworthy. Last year START-UP flagged a handful...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.